<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03295682</url>
  </required_header>
  <id_info>
    <org_study_id>CONNECT</org_study_id>
    <nct_id>NCT03295682</nct_id>
  </id_info>
  <brief_title>Registry in Patients With Thoracoabdominal Aneurysms</brief_title>
  <acronym>CONNECT</acronym>
  <official_title>Registry in Patients With Thoracoabdominal Aneurysms Treated With Multi-branch Stent Grafts Tailored to Their Individual Anatomies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JOTEC GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JOTEC GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study patients will be observed, who receive a multi-branch stent graft tailored to
      the patients anatomy for the endovascular treatment of a thoracoabdominal aortic aneurysm
      Crawford type I, II, III, IV or V.

      The objective of this study is to evaluate clinical and technical success as well as safety
      and feasibility of the multi-branch stent graft Systems used in endovascular treatment of
      thoracoabdominal aortic aneurysms that cannot be treated with commercially available devices.
      Primary endpoint of this study is the rate of patients with stable or decreasing aneurysm
      size at 12 months follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study patients will be observed, who receive a multi-branch stent graft tailored to
      the patient´s anatomy for the endovascular treatment of a thoracoabdominal aortic aneurysm
      Crawford type I, II, III, IV or V. Participating physicians will be asked to provide their
      observations collected during routine care for patients he/she had decided to treat with a
      multi-branch stent graft produced by JOTEC GmbH. Informed consent of the patients to allow
      the use of their clinical records for the purpose of this observational study will be
      obtained before data are being collected.

      The period of data collection will be 36 months from the intervention for each patient. A
      risk based source data verification will be performed. CT angiograms will be evaluated by a
      CoreLab.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Rate of patients with stable or decreasing aneurysm size at 12 months follow-up (measured by CoreLab)</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>Decreasing size: &gt;/= 5mm Increasing size: &lt;/= 5mm compared to first post-operative CT angiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all cause mortality</measure>
    <time_frame>intra-op, post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with aneurysm rupture</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with main adverse events (product-related, procedure-related, aneurysm-related)</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of interventions in peri-operative periods (all related interventions until index procedure)</measure>
    <time_frame>intra-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of reinterventions</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with endoleaks type Ia, Ib, II, III, IV, V and of unknown origin</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with multi-branch stent graft migration</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with loss of device integrity</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with primary / secondary patency of branch vessels</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with stent graft infection</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with primary / secondary technical success</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with primary / secondary clinical success</measure>
    <time_frame>post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with removal or failure to implant the multi-branch stent graft</measure>
    <time_frame>intra-op, post-op until 36 months follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thoracoabdominal Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular thoracoabdominal aneurysm repair</intervention_name>
    <description>Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total number of 40 male and female patients with asymptomatic thoracoabdominal aortic
        aneurysm, treated with a multi-branch stent graft system.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients must have a thoracoabdominal aneurysm type Crawford type I, II, III, IV, or V

          -  Patients must have a suitable proximal landing area

          -  Patients must have a suitable distal landing area in the abdominal aorta or the iliac
             arteries

          -  Patients must have suitable access vessels

          -  Patients must be available for the appropriate follow-up times for the duration of the
             study

          -  Patients have signed the informed consent before intervention

        Exclusion Criteria:

          -  Patients with infectious aneurysm

          -  Patients with inflammatory aneurysm

          -  Patients with ruptured or symptomatic aneurysm

          -  Patients with traumatic aneurysm

          -  Patients with aortic dissection

          -  Patients who have a congenital degenerative collagen disease or connective tissue
             disorder

          -  Patients with thrombocytopenia

          -  Patients with an eGFR &lt; 45ml/min/1.73m2 before the intervention

          -  Patients with untreated hyperthyroidism

          -  Patients with malignancy needing chemotherapy or radiation

          -  Patients that will be treated or are treated with iliac branch devices

          -  Patients pre-treated with Nellix (Endologix) or Ovation (Endologix) or Altura (Lombard
             Medical) stent grafts

          -  Patients who are enrolled in another clinical study

          -  Patients with life expectancy of less than 36 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert Schelzig, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Uniklinikum Düsseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heike Fischer, Dr.</last_name>
    <phone>+49 151 153 97 110</phone>
    <email>heike.fischer@jotec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uniklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert Schelzig, Professor</last_name>
      <phone>+49 211 81 17090</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

